Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216048 | 0.93 | SCN3A (0.47) | SCN3A | |
| SCHEMBL9223074 | 0.89 | SCN3A (0.64) | SCN3AKCNH2 | |
| SCHEMBL9216059 | 0.85 | SCN3A (0.45) | SCN3A | |
| SCHEMBL9215988 | 0.85 | MAOB (0.46) | KCNH2 | |
| SCHEMBL9215265 | 0.84 | LIPG (0.49) | — | |
| SCHEMBL9220961 | 0.84 | SCN3A (0.51) | SCN3AKCNH2 | |
| SCHEMBL9215229 | 0.84 | SCN3A (0.53) | SCN3AKCNH2 | |
| SCHEMBL9216479 | 0.81 | MAOB (0.54) | — | |
| SCHEMBL9217208 | 0.81 | MAOB (0.51) | SCN3AKCNH2 | |
| SCHEMBL9488175 | 0.80 | PPARD (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995002575-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | claimed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-1995002575-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | SCN3A 2704/4885KCNH2 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.